Last reviewed · How we verify
Bermekimab Monoclonal Antibody
Bermekimab is a monoclonal antibody that blocks IL-1β, a key pro-inflammatory cytokine, to reduce inflammation and immune activation.
Bermekimab is a monoclonal antibody that blocks IL-1β, a key pro-inflammatory cytokine, to reduce inflammation and immune activation. Used for Inflammatory conditions (Phase 2 development).
At a glance
| Generic name | Bermekimab Monoclonal Antibody |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Drug class | IL-1β inhibitor monoclonal antibody |
| Target | IL-1β (Interleukin-1 beta) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Bermekimab binds to and neutralizes interleukin-1 beta (IL-1β), a central mediator of innate immune responses and inflammation. By inhibiting IL-1β signaling, the drug reduces the production of downstream inflammatory mediators and dampens excessive inflammatory responses. This mechanism is intended to treat conditions driven by IL-1β-mediated inflammation.
Approved indications
- Inflammatory conditions (Phase 2 development)
Common side effects
- Infection risk
- Injection site reactions
- Infusion-related reactions
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (PHASE2)
- A Study of Bermekimab in Patients With Hidradenitis Suppurativa (PHASE2)
- A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (PHASE3)
- A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |